Abstract
β-Lactamases hydrolyze β-lactam antibiotics and are major determinants of antibiotic resistance in Gram-negative pathogens. Enmetazobactam (formerly AAI101) and tazobactam are penicillanic acid sulfone (PAS) β-lactamase inhibitors that differ by an additional methyl group on the triazole ring of enmetazobactam, rendering it zwitterionic. In this study, ultrahigh-resolution X-ray crystal structures and mass spectrometry revealed the mechanism of PAS inhibition of CTX-M-15, an extended-spectrum β-lactamase (ESBL) globally disseminated among Enterobacterales. CTX-M-15 crystals grown in the presence of enmetazobactam or tazobactam revealed loss of the Ser70 hydroxyl group and formation of a lysinoalanine cross-link between Lys73 and Ser70, two residues critical for catalysis. Moreover, the residue at position 70 undergoes epimerization, resulting in formation of a d-amino acid. Cocrystallization of enmetazobactam or tazobactam with CTX-M-15 with a Glu166Gln mutant revealed the same cross-link, indicating that this modification is not dependent on Glu166-catalyzed deacylation of the PAS-acylenzyme. A cocrystal structure of enmetazobactam with CTX-M-15 with a Lys73Ala mutation indicates that epimerization can occur without cross-link formation and positions the Ser70 Cβ closer to Lys73, likely facilitating formation of the Ser70-Lys73 cross-link. A crystal structure of a tazobactam-derived imine intermediate covalently linked to Ser70, obtained after 30 min of exposure of CTX-M-15 crystals to tazobactam, supports formation of an initial acylenzyme by PAS inhibitors on reaction with CTX-M-15. These data rationalize earlier results showing CTX-M-15 deactivation by PAS inhibitors to involve loss of protein mass, and they identify a distinct mechanism of β-lactamase inhibition by these agents.
Original language | English |
---|---|
Article number | e01793-21 |
Journal | mBio |
Volume | 13 |
Issue number | 3 |
Early online date | 25 May 2022 |
DOIs | |
Publication status | E-pub ahead of print - 25 May 2022 |
Bibliographical note
Funding Information:These studies were supported by research grants from Allecra Therapeutics to J.S. and R.A.B. and from the Medical Research Council to C.L.T. and J.S. (MR/T016035/1) and by the U.K. Biotechnology and Biological Sciences Research Council-funded South West Biosciences Doctoral Training Partnership (training grant reference BB/J014400/1) through a studentship to C.L.T. The study was also supported in part by funds and/or facilities provided by the Cleveland Department of Veterans Affairs, the Veterans Affairs Merit Review Program BX002872 to K.M.P.-W. from the U.S. Department of Veterans Affairs Biomedical Laboratory Research and Development Service. This study was also supported in part by funds and/or facilities provided by the Cleveland Department of Veterans Affairs, award number 1I01BX001974, to R.A.B. from the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development and from the Geriatric Research Education and Clinical Center VISN 10.
Publisher Copyright:
© 2022 American Society for Microbiology. All rights reserved.
Keywords
- enmetazobactam
- AAI101
- tazobactam
- inhibitor
- antibiotic resistance
- CTX-M15
- AMR